Akebia Therapeutics Prices Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Akebia Therapeutics (AKBA) Moves into Oversold Territory Following Equity Offering
April 17, 2015 3:54 PM EDTAkebia Therapeutics (Nasdaq: AKBA) is notably lower Friday after pricing a 7,272,727 share common stock offering at $8.25 each. But, investors might do well to keep an eye on the name.
The 14-day money flow index is at 10.6 percent, which is well below the 20 percent... More
Akebia Therapeutics (AKBA) Prices 7.27M Common Offering at $8.25/Share
April 17, 2015 6:10 AM EDTAkebia Therapeutics (NASDAQ: AKBA) announced the pricing of an underwritten public offering of 7,272,727 shares of common stock at a price to the public of $8.25 per share. The net proceeds of the offering are expected to be approximately $56.1 million, after deducting underwriting discounts and commissions and... More
